Thursday, November 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 6, 2026

SAP Puts the Autonomous Enterprise to Work

View original at finance.yahoo.com
SAP Puts the Autonomous Enterprise to Work Joule Work, Joule Assistants and SAP Business AI Platform help organizations turn business AI into trusted outcomes across every core function…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Autonomous Enterprise has arrived; with Joule and SAP Autonomous Suite on SAP Business AI Platform, SAP helps organizations connect intelligence across every function to deliver trusted business outcomes.

    60% confidence

  • Morgan Foods is putting pieces in place for agentic adoption; the biggest shift will be from reactive to predictive, with agents connecting demand signals, inventory levels and supplier status.

    60% confidence

  • Novartis co-developed and recently launched a pilot of SAP's Joule Sourcing Assistant; the vision is for AI agents to handle manual work so sourcing professionals can focus on strategy, supplier engagement and value creation.

    60% confidence

  • SAP's Billing Assistant brings greater intelligence to the error-prone billing process, helping identify potential issues earlier to deliver better client outcomes.

    60% confidence

  • Nestlé's S/4HANA transformation across 140 countries creates a connected digital core; Joule and the Accounts Receivable Assistant can prioritize collections by risk and business context and recommend next best actions.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
SAP Puts the Autonomous Enterprise to Work — Source | Via News | Via News